All In Biotech

Drug Trial Radar · NCT04573920

Atrasentan in Patients With Proteinuric Glomerular Diseases

A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases

Last checked: Nov 20, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

103

Actual

Start

Mar 15, 2021

Primary completion

Jul 2, 2024

Study completion Oct 27, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.

Conditions

  • IgA Nephropathy
  • Focal Segmental Glomerulosclerosis
  • Alport Syndrome
  • Diabetic Kidney Disease
  • Diabetic Nephropathy Type 2
  • Immunoglobulin A Nephropathy

Interventions

  • AtrasentanDrug

    Film-coated tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in proteinuria for IgAN, FSGS, and Alport syndrome patients receiving 0.75 mg atrasentan QDTime frame: Up to Week 12 or approximately 3 months
  2. Change in albuminuria for DKD patientsTime frame: Up to Week 12 or approximately 3 months
  3. Change in proteinuria for FSGS patients at 1.5 mg doseTime frame: Up to Week 24 or approximately 6 months
  4. Change in proteinuria for FSGS patients at 1.5 mg doseTime frame: Up to Week 30 or approximately 7.5 months

Locations

33 sites in 6 countries. Site status is shown where the registry gives one.

  • Kidney Disease Medical Group

    Glendale, California

  • Academic Medical Research Institute

    Los Angeles, California

  • North America Research Institute

    San Dimas, California

  • Stanford U School Of Medicine

    Stanford, California

  • Colorado Kidney Care Nephrology

    Denver, Colorado

  • Northwest Louisiana Nephrology Research

    Shreveport, Louisiana

  • Tufts Medical Center

    Boston, Massachusetts

  • Uni of Minnesota Hos and Clinics

    Minneapolis, Minnesota

  • DaVita Clinical Research

    Las Vegas, Nevada

  • Mountain Kidney And Hyper Associa

    Asheville, North Carolina

  • Brookview Hills Research Assoc

    Winston-Salem, North Carolina

  • Baylor Scott and White

    Dallas, Texas

  • Prolato Clinical Research Center

    Houston, Texas

  • Milwaukee Nephrologists SC

    Wauwatosa, Wisconsin

  • Novartis Investigative Site

    St Leonards, Australia

  • Novartis Investigative Site

    Gosford, New South Wales, Australia

  • Novartis Investigative Site

    Herston, Queensland, Australia

  • Novartis Investigative Site

    Clayton, Victoria, Australia

  • Novartis Investigative Site

    Reservoir, Victoria, Australia

  • Novartis Investigative Site

    St Albans, Victoria, Australia

  • Novartis Investigative Site

    Roma, RM, Italy

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Cheonan, Chungcheongnam-do, South Korea

  • Novartis Investigative Site

    Anyang-si, Gyeonggi-do, South Korea

  • Novartis Investigative Site

    Seoul, Korea, South Korea

  • Novartis Investigative Site

    Barcelona, Spain

  • Novartis Investigative Site

    Lugo, Spain

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Majadahonda, Spain

  • Novartis Investigative Site

    Port de Sagunt, Valencia, Spain

  • Novartis Investigative Site

    London, United Kingdom

  • Novartis Investigative Site

    Sheffield, South Yorkshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.